LUMA Vision
LUMA Vision is an Irish-German medical device company developing VERAFEYE, a catheter-based 4D cardiac imaging and navigation platform for interventional electrophysiology. It sells capital equipment and consumables to cardiac hospitals and EP labs targeting atrial fibrillation ablation.
- Company typePrivate
- Founded2017
- HeadquartersHarold's Cross, Ireland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What LUMA Vision does
LUMA Vision (formerly OneProjects), founded in 2017 by Fionn Lahart and Christoph Hennersperger, is an Irish-German privately held medical device company headquartered in Dublin with an engineering and R&D center in Munich. The company develops VERAFEYE, a catheter-based 4D cardiac imaging and navigation platform designed for interventional electrophysiology (EP) and structural heart procedures. VERAFEYE integrates proprietary hardware — including a novel ultrasound-enabled catheter with an orbital, contact-free field of view — with a software processing engine and machine learning capabilities to deliver real-time, CT-quality volumetric visualization of the beating heart. Key features include Rapid Digital Anatomy (RDA), which reconstructs both atrial chambers in under 60 seconds, and magnetic tracking of third-party therapeutic catheters, enabling a streamlined two-catheter ablation workflow.
The company serves cardiac electrophysiologists and EP labs at hospitals and academic medical centers, targeting atrial fibrillation (AFib) ablation, complex arrhythmia treatment, and structural heart interventions. The intended customer pain point is the limited imaging visibility during endovascular procedures, where current 2D intracardiac echo and fluoroscopy produce repeat procedure rates of 2–4 times per patient. LUMA Vision's business model is anchored on capital equipment sales of the VERAFEYE platform combined with recurring single-use catheter consumables for ablation procedures, sold direct to leading cardiac hospitals and academic medical centers through an enterprise field-sales motion.
As of early 2026, LUMA Vision remains pre-commercial. The company has completed first-in-human procedures at Mater Private Network in Dublin (January 2025), run 15 procedures at KBC Split in Croatia in collaboration with CardioFocus, and enrolled patients in a Prague-based study. A 510(k) application has been submitted to the FDA with a commercial launch targeted for 2026. The company has raised approximately $51 million across multiple funding rounds from institutional investors including EQT Life Sciences, Atlantic Bridge Ventures, imec.xpand, the European Innovation Council, LSP, Bayern Kapital, and Enterprise Ireland, plus non-dilutive grant funding from the Disruptive Technologies Innovation Fund and the EIC Accelerator.
LUMA Vision firmographics
Firmographics- Name
- LUMA Vision
- Legal name
- LUMA Vision Ltd.
- Website
- https://lumavision.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- LUMA Vision is an Irish-German medical device company developing VERAFEYE, a catheter-based 4D cardiac imaging and navigation platform for interventional electrophysiology. It sells capital equipment and consumables to cardiac hospitals and EP labs targeting atrial fibrillation ablation.
- Ownership category
- akta.pro rank
LUMA Vision industry classification
Industry- Product category
- Cardiac Imaging Systems
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Electrophysiology Mapping & Ablation Systems (HLAHAFAD)
- akta.pro secondary industries
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB), Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)
Keywords
Where LUMA Vision is headquartered
LocationHeadquarters
- HQ city
- Harold's Cross
- HQ country
- Ireland
- HQ region
- Europe
Offices2 records
Markets served
LUMA Vision business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- VERAFEYE Platform System: Sale of medical device capital equipment including the VERAFEYE imaging platform, catheter-based hardware, and associated software systems to hospitals and cardiac centers.
- Catheter Consumables: Single-use catheters and procedural consumables for cardiac ablation and electrophysiology procedures.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
LUMA Vision product offering
Product offeringCore offering
VERAFEYE is an end-to-end catheter-based 4D cardiac imaging and navigation platform that integrates a proprietary ultrasound-enabled orbital-view catheter, hardware console, software processing engine, and machine learning to provide real-time volumetric visualization of the beating heart during interventional electrophysiology procedures. The platform is sold as capital equipment to hospitals and cardiac centers, paired with single-use catheters as recurring consumables, and targets atrial fibrillation ablation and other complex arrhythmia interventions.
Product overview
LUMA Vision operates at the intersection of hardware, software, and machine learning to deliver a single unified platform — VERAFEYE™ — for interventional cardiac imaging and navigation. VERAFEYE™ integrates a novel ultrasound-enabled catheter with orbital view imaging, a software-defined processing engine, and AI-powered features including the Rapid Digital Anatomy (RDA) module. The platform captures real-time 4D intracardiac imaging, magnetically tracks third-party catheters, and automatically reconstructs digital anatomical models, all within a single system designed to unify fragmented EP workflows. There are no standalone modules or separate product tiers — the VERAFEYE platform delivers its full capabilities as a cohesive end-to-end solution for cardiologists and electrophysiologists.
Differentiator
Problem solved
Functional benefit
Brands
- VERAFEYE™: A novel end-to-end platform technology providing 4D cardiac imaging and navigation for interventional electrophysiology and structural heart procedures. The platform delivers CT-quality visualization in seconds, combining live 2D and 4D intra-procedural imaging with digital anatomical models.
Products and services
- VERAFEYE Visualization and Guidance Platform End-to-end, catheter-based 4D cardiac imaging and navigation platform providing real-time volumetric visualization of the beating heart, automatic digital anatomy generation, and magnetic tracking of third-party catheters for interventional electrophysiology and structural heart procedures. Sold as capital equipment to hospitals and cardiac centers performing catheter ablation for atrial fibrillation and other arrhythmias.
Quantifiable outcome
- CT-quality reconstructions of atrial chambers in under 60 seconds
- +2 more outcomes
Companies that use LUMA Vision
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
LUMA Vision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature6 records
LUMA Vision partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered strategic, foundational and supporting.
- CardioFocus, Inc.strategicCollaboration for clinical study evaluating VERAFEYE-guided persistent atrial fibrillation ablation procedures. Demonstrated integration with CardioFocus ablation technology and streamlined two-catheter workflow.
- Trinity College DublinfoundationalAcademic institution from which LUMA Vision was spun out, originating from BioInnovate Ireland program.
- BioInnovate IrelandfoundationalMedical device innovation program that provided the foundation and origin for LUMA Vision company.
- EIT HealthsupportingEuropean Institute of Innovation and Technology Health initiative supporting healthcare innovation projects.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
LUMA Vision competitors and assessment
Company assessmentDirect peers
- Stereotaxis: Developer of robotic magnetic navigation systems for cardiac ablation procedures. Comparable as a smaller EP-focused technology company offering alternative catheter navigation in the same electrophysiology lab environment.
- Acutus Medical: Cardiac electrophysiology company developing mapping and imaging technologies for arrhythmia treatment. Closely comparable as a smaller EP-focused competitor with novel cardiac imaging/navigation technology targeting similar electrophysiologists.
- CardioFocus: Developer of catheter-based laser ablation systems for atrial fibrillation. Directly comparable as a strategic partner of LUMA Vision (collaborated on the KBC Split clinical study) targeting the same AF ablation procedure space.
Emerging players
- CathVision: Developer of advanced cardiac electrophysiology recording and 3D mapping systems. Comparable as a smaller EP-focused technology company providing mapping/imaging tools in the same electrophysiology lab setting.
- Kardium: Developer of catheter-based systems for atrial fibrillation treatment (Globe Mapping and Ablation System). Comparable emerging player targeting the same AF ablation indication with novel catheter-based technology.
- NaviGate Cardiac Structures: Developer of catheter-based delivery systems for structural heart interventions including mitral and tricuspid valves. Comparable as a smaller catheter-based cardiac device company operating in the same interventional cardiology/structural heart space.
- MedLumics: Developer of optically-based cardiac ablation and imaging catheter systems using photonics technology. Comparable emerging player in catheter-based cardiac ablation with novel imaging-enabled approach.
Broad incumbents
- Biosense Webster (Johnson & Johnson): J&J's electrophysiology business and global leader in EP mapping and ablation catheters (CARTO system). Directly competes with VERAFEYE in the same cardiac EP labs and arrhythmia ablation procedures.
- Boston Scientific: Major incumbent in cardiac EP with mapping systems (Rhythmia) and ablation catheters. Competes directly for the same EP lab capital equipment and procedural catheter purchases that VERAFEYE targets.
- Abbott: Broad medtech incumbent with significant EP portfolio including mapping systems (EnSite X) and ablation catheters. Competes with VERAFEYE for EP lab equipment, ablation workflows, and structural heart procedure guidance.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
LUMA Vision social profiles
Digital presenceLUMA Vision financial estimates
Financial estimateRevenue estimate
Valuation estimate
LUMA Vision leadership team
Management profileNumber of profiles
Profiles13 records
LUMA Vision funding detail
Funding detailFunding overview
Funding rounds6 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LUMA Vision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LUMA Vision
What does LUMA Vision do?
VERAFEYE is an end-to-end catheter-based 4D cardiac imaging and navigation platform that integrates a proprietary ultrasound-enabled orbital-view catheter, hardware console, software processing engine, and machine learning to provide real-time volumetric visualization of the beating heart during interventional electrophysiology procedures. The platform is sold as capital equipment to hospitals and cardiac centers, paired with single-use catheters as recurring consumables, and targets atrial fibrillation ablation and other complex arrhythmia interventions.
Is LUMA Vision a public or private company?
LUMA Vision is a private company. It is classified as venture growth investor backed and is currently operating.
When was LUMA Vision founded?
LUMA Vision was founded in 2017. It employs 51 to 100 people.
Where is LUMA Vision based?
LUMA Vision is headquartered in Harold's Cross, Ireland, in the Europe region.
How does LUMA Vision make money?
Two revenue lines are on record. VERAFEYE Platform System is the primary driver. The others are catheter Consumables.
Who are LUMA Vision's main competitors?
Direct peers on record are Stereotaxis, Acutus Medical and CardioFocus. Emerging players are CathVision, Kardium, NaviGate Cardiac Structures and MedLumics. Broad incumbents are Biosense Webster (Johnson & Johnson), Boston Scientific and Abbott.
Does LUMA Vision have an API?
No public API is recorded for LUMA Vision.
What industry is LUMA Vision in?
LUMA Vision's product category is Cardiac Imaging Systems. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders). Its NAICS code is 334510 and its SIC code is 3841.